Formulary
Plerixafor: Indications, Dosing, Side Effects and Interactions
Plerixafor is a chemokine receptor antagonist.
MedNext Academy | 3 min read
Plerixafor: Indications, Dosing, Side Effects and Interactions
Plerixafor is a chemokine receptor antagonist.
Drug action
Plerixafor is a chemokine receptor antagonist.
Indications and dose
**Mobilise haematopoietic stem cells to peripheral blood**
- **Adult** (By Subcutaneous Injection): (body-weight 84 kg and above) 240 micrograms/kg daily usually for 2-4 days (and up to 7 days), to be administered 6-11 hours before initiation of apheresis, dose to be given following 4 days treatment with a granulocyte-colony stimulating factor; maximum 40 mg per day.
**Mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma or solid malignant tumours (specialist use only) for plerixafor**
- **Child 1-17 years** (By subcutaneous injection): 240 micrograms/kg daily usually for 2-4 days (and up to 7 days), to be administered 6-11 hours before initiation of apheresis, dose to be given following 4 days treatment with a granulocyte-colony stimulating factor; maximum 40 mg per day.
Side effects
Common or very common Arthralgia; constipation; diarrhoea; dizziness; dry mouth; erythema; fatigue; flatulence; gastrointestinal discomfort; headache; hyperhidrosis; malaise; musculoskeletal pain; nausea; oral hypoaesthesia; sleep disorders; vomiting Frequency not known Postural hypotension; splenomegaly; syncope
Interactions
**Other interactions (3):**
- In vitro tests showed that plerixafor was not metabolised by P450 CYP enzymes, did not inhibit or induce P450 CYP enzymes.
- Plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an in vitro study.
- In clinical studies of patients with Non-Hodgkin's lymphoma, the addition of rituximab to a mobilisation regimen of plerixafor and G-CSF did not impact patient safety or CD34+ cell yield.
Pregnancy
Manufacturer advises avoid unless essential- teratogenic in animal studies.
Breast feeding
Manufacturer advises avoid-no information available.
Renal impairment
No information available if creatinine clearance less than 20 mL/minute. Dose adjustments Manufacturer advises reduce dose to 160 micrograms/kg (maximum 27 mg) daily if creatinine clearance 20-50 mL/minute. See Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Plerixafor in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

